EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing

Marco Lincango iD, Verónica Andreoli iD, Hernán García Rivello iD, Andrea Bender iD, Ana I Catalán iD, Marilina Rahhal iD, Rocío Delamer iD, Mariana Asinari iD, Adrián Mosquera Orgueira iD, María Belén Castro iD, María José Mela Osorio iD, Alicia Navickas iD und 5 weitere

Annals of Laboratory Medicine · 2025

DOI: 10.3343/alm.2024.0089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Laboratory Medicine, 2025. Verfasst von Marco Lincango und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Genética Hematológica, Instituto de Medicina Experimental (IMEX-CONICET)/Academia Nacional de Medicina, Ciudad de Buenos Aires, Argent…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, High-Throughput Nucleotide Sequencing, Area Under Curve, ROC Curve. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agencia Nacional de Promoción Científica y Tecnológica, Consejo Nacional de Investigaciones Científicas y Técnicas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Molecular International Prognostic Scoring System (IPSS-M) has improved the prediction of clinical outcomes for myelodysplastic syndromes (MDS). The Artificial Intelligence Prognostic Scoring System for MDS (AIPSS-MDS), based on classical clinical parameters, has outperformed the IPSS, revised version (IPSS-R). For the first time, we validated the IPSS-M and other molecular prognostic models and compared them with the established IPSS-R and AIPSS-MDS models using data from South American patients.

Methods

Molecular and clinical data from 145 patients with MDS and 37 patients with MDS/myeloproliferative neoplasms were retrospectively analyzed.

Results

Prognostic power evaluation revealed that the IPSS-M (Harrell's concordance [C]-index: 0.75, area under the receiver operating characteristic curve [AUC]: 0.68) predicted overall survival better than the European MDS (EuroMDS; C-index: 0.72, AUC: 0.68) and Munich Leukemia Laboratory (MLL) (C-index: 0.70, AUC: 0.64) models. The IPSS-M prognostic discrimination was similar to that of the AIPSS-MDS model (C-index: 0.74, AUC: 0.66) and outperformed the IPSS-R model (C-index: 0.70, AUC: 0.61). Considering simplified low- and high-risk groups for clinical management, after restratifying from IPSS-R (57% and 32%, respectively, hazard ratio [HR]: 2.8; P=0.002) to IPSS-M, 12.6% of patients were upstaged, and 5% were downstaged (HR: 2.9; P=0.001). The AIPSS-MDS recategorized 51% of the low-risk cohort as high-risk, with no patients being downstaged (HR: 5.6; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesHigh-Throughput Nucleotide SequencingArea Under CurveROC CurveHumansPrognosisMiddle AgedAgedFemaleMaleRetrospective StudiesAdultAged, 80 and overKaplan-Meier EstimateProportional Hazards Models

Stichwörter der Autor:innen

Artificial Intelligence Prognostic Scoring SystemModelMolecular International Prognostic Scoring SystemMyelodysplastic syndromePrognosticRisk assessmentSouth AmericaSurvival analysisTherapy

Autor:innen und Institutionen

  • Laboratorio de Genética Hematológica, Instituto de Medicina Experimental (IMEX-CONICET)/Academia Nacional de Medicina, Ciudad de Buenos Aires, Argentina.
  • Hospital Universitario Privado de Córdoba, Córdoba, Argentina.
  • Hospital Italiano de Buenos Aires, Ciudad de Buenos Aires, Argentina.
  • Laboratorio de Especialidades Bioquímicas, Bahía Blanca, Argentina.
  • Hospital de Clínicas "Dr. Manuel Quintela," Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
  • Hospital de Alta Complejidad "El Cruce Nestor Kirchner," Florencio Varela, Argentina.

ORCID-Profile: Marco Lincango, Verónica Andreoli, Hernán García Rivello, Andrea Bender, Ana I Catalán, Marilina Rahhal, Rocío Delamer, Mariana Asinari, Adrián Mosquera Orgueira, María Belén Castro, María José Mela Osorio, Alicia Navickas, Sofia Grille, Evangelina Agriello, Jorge Arbelbide, Ana Lisa Basquiera, Carolina B Belli

Förderung

  • Agencia Nacional de Promoción Científica y Tecnológica
  • Consejo Nacional de Investigaciones Científicas y Técnicas

Zitieren

APA

Lincango, M., Andreoli, V., Rivello, H. G., Bender, A., Catalán, A. I., Rahhal, M., Delamer, R., Asinari, M., Orgueira, A. M., Castro, M. B., Osorio, M. J. M., Navickas, A., Grille, S., Agriello, E., Arbelbide, J., Basquiera, A. L., & Belli, C. B. (2025). Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing. Annals of Laboratory Medicine. https://doi.org/10.3343/alm.2024.0089

Vancouver

Lincango M, Andreoli V, Rivello HG, Bender A, Catalán AI, Rahhal M, et al. Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing. Annals of Laboratory Medicine. 2025. doi:10.3343/alm.2024.0089

BibTeX
@article{Lincango2025,
  author = {Lincango, Marco and Andreoli, Verónica and Rivello, Hernán García and Bender, Andrea and Catalán, Ana I and Rahhal, Marilina and Delamer, Rocío and Asinari, Mariana and Orgueira, Adrián Mosquera and Castro, María Belén and Osorio, María José Mela and Navickas, Alicia and Grille, Sofia and Agriello, Evangelina and Arbelbide, Jorge and Basquiera, Ana Lisa and Belli, Carolina B},
  title = {Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing},
  journal = {Annals of Laboratory Medicine},
  year = {2025},
  doi = {10.3343/alm.2024.0089}
}
Kostenlos starten →